Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00871195 · ClinicalTrials.gov registry record
A Noninvasive Test for Fetal RHD Genotype
A clinical trial, sponsored by Sequenom.
- Completed
- Registry status
- 520
- Enrollment target
NCT00871195: Completed study, sponsored by Sequenom.
NCT00871195 is a clinical trial that has completed, run by Sequenom. The registered enrollment target is 520 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00871195 has completed, sponsored by Sequenom.
- COMPLETED
- Registry status
- 520 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the performance of Sequenom's noninvasive test for fetal RHD genotype. The test uses MALDI-TOF mass spectrometry to detect DNA. The study is specifically designed to determine whether RHD typing using free fetal DNA in maternal circulation can accurately predict the neonatal RhD phenotype at birth.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2009-04 |
| Est. Completion | 2012-04 |
What the finished NCT00871195 record still lists
NCT00871195 is an observational study that tracks outcomes without assigning an intervention. The registered 520 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00871195 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00871195 about?
NCT00871195 is a clinical study titled "A Noninvasive Test for Fetal RHD Genotype". The objective of this study is to evaluate the performance of Sequenom's noninvasive test for fetal RHD genotype. The test uses MALDI-TOF mass spectrometry to detect DNA. The study is specifically designed to determine whether RHD typing using free fetal DNA in maternal circulation can accurately pr...
What is the current status of trial NCT00871195?
This trial is currently completed. The enrollment target is 520 participants. The study started on 2009-04. Estimated completion is 2012-04.
Who is sponsoring clinical trial NCT00871195?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
- NCT04656496 · 520 participants · NA
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
- NCT05445778 · 520 participants · Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
- NCT05498428 · 520 participants · Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia